Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415595 | 1.00 | HCRTR1 (0.52) | HCRTR1HCRTR2DRD4HPGDRXFP1 | |
| SCHEMBL1340950 | 1.00 | HCRTR1 (0.52) | HCRTR1HCRTR2DRD4HPGDRXFP1 | |
| SCHEMBL3415599 | 1.00 | HCRTR1 (0.52) | HCRTR1HCRTR2DRD4HPGDRXFP1 | |
| SCHEMBL3414977 | 0.94 | HCRTR1 (0.49) | HCRTR1HCRTR2DRD4HPGDMEN1 | |
| SCHEMBL3414972 | 0.94 | HCRTR1 (0.49) | HCRTR1HCRTR2DRD4HPGDMEN1 | |
| SCHEMBL1340453 | 0.94 | HCRTR1 (0.49) | HCRTR1HCRTR2DRD4HPGDMEN1 | |
| SCHEMBL1340454 | 0.94 | HCRTR1 (0.49) | HCRTR1HCRTR2DRD4HPGDMEN1 | |
| SCHEMBL1339033 | 0.94 | HCRTR1 (0.49) | HCRTR1HCRTR2DRD4 | |
| SCHEMBL1339036 | 0.94 | HCRTR1 (0.49) | HCRTR1HCRTR2DRD4 | |
| SCHEMBL3431383 | 0.94 | HCRTR1 (0.46) | HCRTR1HCRTR2DRD4HPGDRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063099-B2 | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-22 | — | — | US | claimed |
| EP-2185512-B1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-29 | — | — | EP | claimed |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | claimed |
| EP-2185512-B1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885DRD4 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.